Last reviewed · How we verify
prostaglandin E1 analogue — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
prostaglandin E1 analogue (prostaglandin E1 analogue) — Nwali Matthew Igwe.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| prostaglandin E1 analogue TARGET | prostaglandin E1 analogue | Nwali Matthew Igwe | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- prostaglandin E1 analogue CI watch — RSS
- prostaglandin E1 analogue CI watch — Atom
- prostaglandin E1 analogue CI watch — JSON
- prostaglandin E1 analogue alone — RSS
Cite this brief
Drug Landscape (2026). prostaglandin E1 analogue — Competitive Intelligence Brief. https://druglandscape.com/ci/prostaglandin-e1-analogue. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing